These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 28953116)

  • 1. Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.
    Demarco M; Lorey TS; Fetterman B; Cheung LC; Guido RS; Wentzensen N; Kinney WK; Poitras NE; Befano B; Castle PE; Schiffman M
    J Low Genit Tract Dis; 2017 Oct; 21(4):261-267. PubMed ID: 28953116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.
    Cox JT;
    Arch Pathol Lab Med; 2003 Aug; 127(8):950-8. PubMed ID: 12952506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytology and high risk HPV testing in cervical cancer screening program: Outcome of 3-year follow-up in an academic institute.
    Yang J; Nolte FS; Chajewski OS; Lindsey KG; Houser PM; Pellicier J; Wang Q; Ehsani L
    Diagn Cytopathol; 2018 Jan; 46(1):22-27. PubMed ID: 29048733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.
    Katki HA; Gage JC; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S69-77. PubMed ID: 23519308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
    Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
    Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
    [No Abstract]   [Full Text] [Related]  

  • 6. [Application of high-risk human papillomavirus testing in women with abnormal cytology].
    Ou H; Bian ML; Zhang XY; Chen QY; Li M; Chen Y; Liu J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):608-11. PubMed ID: 18051714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S50-5. PubMed ID: 23519305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reflex Human Papillomavirus Test Results as an Option for the Management of Korean Women With Atypical Squamous Cells Cannot Exclude High-Grade Squamous Intraepithelial Lesion.
    Ryu KJ; Lee S; Min KJ; Kim JW; Hong JH; Song JY; Lee JK; Lee NW
    Oncologist; 2015 Jun; 20(6):635-9. PubMed ID: 25964305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S36-42. PubMed ID: 23519303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of Cervical Precancers by Endocervical Curettage at Colposcopy of Women With Abnormal Cervical Cytology.
    Liu AH; Walker J; Gage JC; Gold MA; Zuna R; Dunn ST; Schiffman M; Wentzensen N
    Obstet Gynecol; 2017 Dec; 130(6):1218-1225. PubMed ID: 29112672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled analysis on the necessity of random 4-quadrant cervical biopsies and endocervical curettage in women with positive screening but negative colposcopy.
    Hu SY; Zhang WH; Li SM; Li N; Huang MN; Pan QJ; Zhang X; Han Y; Zhao FH; Chen W; Qiao YL
    Medicine (Baltimore); 2017 Apr; 96(17):e6689. PubMed ID: 28445270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer.
    Castle PE; Fetterman B; Thomas Cox J; Shaber R; Poitras N; Lorey T; Kinney W
    Obstet Gynecol; 2010 Jul; 116(1):76-84. PubMed ID: 20567171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S28-35. PubMed ID: 23519302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S56-63. PubMed ID: 23519306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining the Longitudinal Risk of CIN 3+ for Piedimonte S; Tsang K; Jembere N; Murphy J; Karapetian T; Gao J; McCurdy B; Sacco J; Kupets R
    J Low Genit Tract Dis; 2024 Jan; 28(1):7-11. PubMed ID: 37906611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
    Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
    Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.
    Gage JC; Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Behrens C; Sharma A; Zhao FH; Cuzick J; Yang ZH; Kinney WK
    Cancer Cytopathol; 2014 Nov; 122(11):842-50. PubMed ID: 25045058
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.